According to the World Health Organization read reviews here.

Is the opportunity to fight for new antiviral strategies to HCV significant because about 180 million people worldwide are HCV infected read reviews here read more . According to the World Health Organization , responding only 30-50 percent of infected patients beneficial to the 48-week pegylated interferon-ribavirin standard.

Aethlon Medical Hemopurifie the developer of a first – in-class medical device is designed infectious diseases. Infectious diseases. Which provides real-time therapeutic Hemopurifie filtration of infectious viruses and immunosuppressive particles and is positioned to address the treatment of drug resistant virus and vaccine. Additionally, the device holds promise in cancer treatment, as studies have demonstrated the Hemopurifie can capture immunosuppressive particles secreted by tumors. The Hemopurifie as a standalone as a standalone therapy and as adjunctive therapy to improve clinical benefit of established therapies. Preclinical studies by researchers representing leading government and non – governmental health organizations have been performed in both the United States and abroad, the efficacy of Hemopurifie in capturing from circulation the viruses that pandemics, including H5N1 Avian Influenza form , documented and dengue haemorrhagic fever from circulation. The company is carrying out studies, from the U.S. Food use of Hemopurifie as broad-spectrum treatment countermeasure against bioterror threats, including smallpox and Ebola, Marburg and Lassa hemorrhagic fever. Regulatory and commercialization initiatives in the United States are presently focused on bioterror threats, while international initiatives toward naturally evolving pandemic threats, and chronic infectious disease conditions including the Human Immunodeficiency Virus and hepatitis C are addressed. Aethlon demonstrated the safety of the Hemopurifie in a 24 – treatment human study at the Apollo Hospital in Delhi, and is currently conducting further human studies at the Fortis Hospital in Delhi. An Investigational an Investigational Device Exemption from the U.S. Food and Drug Administration Hemopurifie Hemopurifie as broad-spectrum treatment countermeasure against category ‘A’bioterror threats. Additional information regarding Aethlon Medical and its Hemopurifie technology is available online at.